Performance Peptides: Frequently asked questions

Kisspeptin-10 increases endogenous testosterone production by stimulating GnRH and LH secretion, but it requires intravenous administration at 1.0–4.0 nmol/kg for measurable effect. Subcutaneous dosing showed inconsistent absorption in trials. It's mechanistically sound for hypogonadism research but logistically complex compared to exogenous testosterone therapy. If your protocol focuses on restoring natural testosterone production rather than supplementation, Kisspeptin-10 is viable. But IV administration limits practical use outside clinical research settings.

Use them only if you have COA documentation showing HPLC purity above 98% and sterility testing results. Without that documentation, you don't know what compound you're using or at what purity. Pre-2025 peptides from unverified suppliers frequently tested at 60–75% purity in third-party analyses. Using them in research produces unreliable data. If no COA exists, discard them and source from a verified 503B facility like Real Peptides.

First, verify the dose and administration route. PT-141 must be administered subcutaneously at 0.75–1.75mg to produce clinical effects. Oral and nasal formulations showed no statistical advantage over placebo in controlled trials. Second, check peptide purity. If sourced from a non-503B supplier, low purity is the most likely cause of treatment failure. Third, assess patient expectations: PT-141 increases desire and arousal but does not directly cause erections; it works upstream of vascular pathways, so patients with severe erectile dysfunction may require combined therapy with PDE5 inhibitors.

If the package feels warm to the touch or the ice packs have fully melted, measure the vial temperature immediately. Lyophilised (freeze-dried) peptides tolerate short-term ambient temperature (up to 25°C for 24–48 hours), but reconstituted peptides degrade rapidly above 8°C. If the peptide was shipped lyophilised and the temperature didn't exceed 30°C, refrigerate it immediately and use as directed. If it was pre-mixed or the vial is visibly cloudy or discoloured, contact the supplier. Protein denaturation is irreversible and renders the peptide inactive.

If you compete in WADA-sanctioned events, TB-500, BPC-157, and AOD-9604 are prohibited in-competition and out-of-competition as of January 2026. Detection windows vary. TB-500 is detectable for approximately 10 days via LC-MS/MS, while BPC-157 clears faster but can still trigger a positive test within 72 hours of administration. Ipamorelin, CJC-1295, and MK-677 remain permitted and can be used without violation. The safest protocol: consult a sports medicine physician familiar with WADA regulations and use only peptides not listed on the current Prohibited List.

For peptides dosed multiple times per week (TB-500, Ipamorelin), administer the missed dose as soon as you remember if fewer than 48 hours have passed, then resume your regular schedule. If more than 48 hours have passed, skip the missed dose and continue on your next scheduled date. Do not double-dose. For daily peptides (BPC-157, MK-677), take the missed dose within 12 hours of the scheduled time; if more than 12 hours late, skip it. Peptide efficacy depends on consistent plasma levels, but occasional missed doses don't negate cumulative benefits.

Use a medical-grade cooler designed for insulin transport. Models like the FRIO wallet maintain 2–8°C through evaporative cooling for 36–48 hours without ice or electricity. Unreconstituted lyophilized peptides tolerate short-term ambient temperature (up to 25°C for 24–48 hours), but pre-mixed solutions must stay refrigerated. Plan travel timing to minimize temperature exposure. Ship peptides to your destination ahead of time if the travel window exceeds your cooler's rated duration.

Resume dosing at your previous schedule without doubling up or attempting to "catch up." Peptide protocols work through consistent signaling over weeks. Missing 2–3 doses does not erase prior progress, but double-dosing to compensate creates erratic plasma levels that disrupt receptor sensitivity. Athletes in multi-week training camps often miss doses due to travel or logistical constraints. Our experience shows that maintaining 80% adherence (dosing 5–6 days per week) still produces measurable results, though slightly delayed compared to perfect adherence.

Water retention occurs in 20–30% of MK 677 users due to elevated aldosterone and cortisol levels during the first 2–4 weeks of use. This is a transient effect. Aldosterone levels normalize as the body adjusts to sustained GH elevation. Reduce sodium intake to 2,000–2,500mg daily during the adaptation period to minimize subcutaneous water accumulation. If retention persists beyond 4 weeks, reduce MK 677 dose by 25% and reassess after 2 weeks.

Extend the protocol to 8–10 weeks before evaluating efficacy. Growth hormone secretagogues create cumulative effects through sustained elevation of IGF-1 (insulin-like growth factor 1), which mediates most of GH's anabolic actions. IGF-1 levels take 4–6 weeks to reach steady-state elevation following consistent GH secretagogue use. Athletes expecting immediate strength gains or body composition changes within the first month misunderstand the mechanism. Peptides optimize biological systems that produce results over weeks, not days.